Celia J. F. Lin

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 652 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +4

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Socrates E. Papapoulos, Kurt Lippuner, Christian Roux et al. · Osteoporosis International · 2015 · 277 citations · Full text

Medicine, Endocrinology, Bone Metabolism +16

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Dinesh Khanna, Christopher P. Denton, Celia J. F. Lin et al. · Annals of the Rheumatic Diseases · 2017 · 258 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease

David Roofeh, Celia J. F. Lin, Jonathan Goldin et al. · Arthritis & Rheumatology · 2021 · 191 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 132 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13